BOULDER, Colo.--(BUSINESS WIRE)--MBio Diagnostics, Inc. today announced it has been awarded two additional patents for its LightDeck® technology, a powerful fluorescence assay illumination and imaging approach. European Patent EP 2627987 A2 titled “Fluidic Assay Cartridge with Controlled Passive Flow” and U.S. Patent US 9739714 B2 titled “Particle Identification System, Cartridge and Associate Methods” cover key elements of MBio’s cartridge-based LightDeck® technology.
MBio Diagnostics develops portable on-the-spot testing technologies for multiple applications, from medical and veterinary diagnostics to water quality testing. The need for rapid assays totals over $8 billion across medical, veterinary, food and environmental testing. The MBio platform combines an easy-to-use reader with a low-cost disposable cartridge that together can provide multiple results in minutes.
Michael Lochhead, MBio’s Chief Technology Officer, said, “The new patents broaden the intellectual property position on our proprietary LightDeck® technology, expanding protection to cover key elements of cartridge fluidics. MBio has developed unique approaches to solving fluid management and detection in these combined opto-fluidic devices, as recognized by the patent offices. These patents will support our efforts to expand the platform’s applicability across a number of applications.”
About MBio Diagnostics
MBio Diagnostics is enabling a new era in rapid, on-the-spot clinical diagnostics and sample testing. Our portable MBio Array System and disposable cartridges provide multiple quantitative answers in minutes. MBio aims to be the platform of choice for leading providers and users of clinical and analytical testing services in all market segments including: medical, veterinary, environmental, food, agricultural and military. www.mbiodx.com